The Hartford Post
SEE OTHER BRANDS

Following the news from Connecticut

The Hartford Post: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Hartford Post.

Press releases published on July 1, 2025

How Trump-Era Tariffs Are Still Affecting Menswear Prices and ContempoSuits.com

How Trump-Era Tariffs Are Still Affecting Menswear Prices and ContempoSuits.com

How Trump-Era Tariffs Are Still Affecting the Menswear Industry: A Conversation with Aaron Sarfati, President and CEO of ContempoSuits.com BRIDGEPORT, CT, UNITED STATES, July 1, 2025 /⁨EINPresswire.com⁩/ -- How Trump-Era Tariffs Are Still Affecting the …

Geezers, Gadgets & Gizmos® Launches to Help Seniors Live Smarter with Tech, Humor, and Heart

Geezers, Gadgets & Gizmos® Launches to Help Seniors Live Smarter with Tech, Humor, and Heart

Geezers, Gadgets …

Blue Orchid Marketing Marks 24 Years with AI-Powered, Client-Tailored Growth

Blue Orchid Marketing Marks 24 Years with AI-Powered, Client-Tailored Growth

Blue Orchid Marketing welcomes Peter Anselmi as Business Development Manager, expanding its reach with AI-enhanced, specialty-specific strategies. DANBURY, CT, UNITED STATES, July 1, 2025 /⁨EINPresswire.com⁩/ -- Blue Orchid Marketing, a trusted name in …

Renewal by Andersen Reported for Making Deceptive Made in USA Claims

Renewal by Andersen Reported for Making Deceptive Made in USA Claims

MADISON, CONN., July 01, 2025 (GLOBE NEWSWIRE) -- Renewal by Andersen, which bills itself as “one of largest replacement window companies in the country,” is deceptively marketing its products as Made in USA in violation of the FTC’s Made in USA Labeling …

BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., July 01, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions